M-A | Androgen receptor signaling inhibitors in addition to Docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. 24 Aug, 2022 | 13:58h | UTC Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis – European Urology